Introducing 428Pharma.

Developing the world's first treatment to prevent relapse in depression

Our Mission

After treatment of the first episode of depression, approximately half of all patients will relapse, and this risk increases for every subsequent episode (70% and 90% after a second and third episode respectively)

After a second relapse patients are defined as treatment resistant (TRD)

30% of TRD patients attempt suicide in their lifetime

Suicide death rate among persons aged 10–24 increased 56% from 2007 through 2017

Prevention of relapse can prevent patients becoming treatment resistant and reduce their suicide risk - there are currently no treatments that reduce relapse in MDD

Our Product

Escitalopram LAI (Long Acting Injectable)

We have a formulation of the worlds first LAI for prevention of relapse in MDD - potential time to market 2028

First depot injection for SSRI for a vast depression market estimated at $15.8Bn in 2025
505(b)(2) truncated development with LOE 2046. PK only approval pathway with FDA
Opportunity to out-license end of phase I